Curis Lifesciences Ltd (CURIS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Curis Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Curis Lifesciences Limited has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Quarter and year ended on September 30, 2026
Others (Uncategorized) · 19 Oct 2026, 10:22 pm
Curis Lifesciences Confirms Corporate Governance Report Exemption for Q2 FY27 Curis Lifesciences Limited has confirmed the non-applicability of Corporate Governance Report submission under Regulation 27(2) of SEBI LODR Regulations for the quarter and half-year ended 30th Sep'26. Being listed on the NSE SME platform (NSE Emerge), the company is exempt under Regulation 15(2)(b) from key corporate governance provisions, excluding Regulation 23 compliance where applicable. A practicing company secretary certificate from Sachin Thakkar & Associates has been submitted confirming this regulatory exemption.
Curis Lifesciences Limited has submitted the Exchange a copy Srutinizers report of 10th Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 01 Oct 2026, 12:01 am
CURIS: Curis Lifesciences Limited has informed the Exchange regarding Proceedings of 10thAnnual General Meeting held on September 29, 2026.
Annual General Meeting · 30 Sept 2026, 12:09 am
Curis Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
Annual General Meeting · 08 Sept 2026, 1:00 am
Curis Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.
Outcome · 08 Sept 2026, 12:30 am
Curis Lifesciences Approves FY26 Director's Report, Sets 10th AGM for 29th Sep'26 Curis Lifesciences Limited's Board of Directors met on 7th Sep'26 and approved the Director’s Report for the financial year ended 31st Mar'26 along with related party transactions. The company scheduled its 10th Annual General Meeting via Video Conferencing for 29th Sep'26 at 12:00 PM, fixing the voting cut-off date as 22nd Sep'26. Additionally, Practicing Company Secretary Sachin Thakkar was appointed as the scrutinizer for the AGM proceedings.
Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 04 Sept 2026, 12:45 am
Curis Lifesciences Limited has informed the Exchange regarding Cessation of Mr Nikhil Purohit as Company Secretary & Compliance Officer of the company w.e.f. September 03, 2026.
Change in Management · 04 Sept 2026, 12:42 am
Curis Lifesciences Announces Resignation of Compliance Officer Nikhil Purohit Curis Lifesciences Ltd. announced the resignation of Mr. Nikhil Purohit from his position as Company Secretary and Compliance Officer, effective from the close of business on 3rd Sep'26. Purohit cited pre-occupancy in other assignments as the reason for his departure. The company confirmed there are no other material reasons prompting this management change.
Curis Lifesciences Limited has informed the Exchange about Joint venture agreement entered into by the company with CUROSUN PHARMACEUTICAL NIG LTD (Nigerian Company) by acquiring 49.95% stake of such company.
Others (Uncategorized) · 14 Aug 2026, 12:31 am
Curis Lifesciences to Acquire 49.95% Stake in Nigerian Pharma Company Curis Lifesciences will acquire a 49.95% stake in Nigeria-based Curosun Pharmaceutical NIG Ltd for a cash consideration of Rs. 5,00,000. The transaction, executed on 12th Aug'26, is a strategic move to expand business and strengthen market presence in the pharmaceutical industry. The target company, engaged in drug importation and distribution, is a private entity with zero turnover. The acquisition does not constitute a related party transaction. This move aligns with Curis's growth initiatives for diversification and market expansion.
Curis Lifesciences Limited has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Quarter and year ended on June 30, 2026
Others (Uncategorized) · 15 Jul 2026, 5:25 pm
Curis Lifesciences Exempt from Corporate Governance Reporting for Q1FY27 Curis Lifesciences announced it is not required to file the Corporate Governance Report under Regulation 27(2) for the quarter ending 30th Jun'26. As a company listed on the NSE SME Platform (NSE Emerge), it is exempt from compliance with SEBI's corporate governance provisions per Regulation 15(2)(b). This exemption applies provided its paid-up equity capital and net worth remain below specified thresholds. A certificate from its Practicing Company Secretary confirming this non-applicability was submitted to the exchange.
Curis Lifesciences Limited has informed the Exchange about Comments of board on the fine levied by the National Stock Exchange (NSE Limited)
Others (Uncategorized) · 14 Jul 2026, 12:58 am
Curis Lifesciences Fined by NSE for Delayed RPT Disclosure; Cites Technical Glitch Curis Lifesciences received a notice from the NSE on 30 Jun'26 regarding a one-day delay in filing its Related Party Transactions (RPT) disclosure for the half-year ended 31 Mar'26. The Board, in its meeting on 13 Jul'26, attributed the delay to unforeseen technical errors on the NEAPS portal, which prevented timely submission. The company has paid the fine of ₹5,900 (₹5,000 plus 18% GST). The Board stated this was a marginal delay due to technical issues and not reflective of its governance standards.
Curis Lifesciences Limited has informed the Exchange regarding Appointment of Mr Devabhai Hamirbhai Jadeja as Non- Executive Independent Director of the company w.e.f. July 13, 2026.
Outcome · 14 Jul 2026, 12:53 am
Curis Lifesciences Appoints New Non-Executive Independent Director Curis Lifesciences has appointed Mr. Devabhai Hamirbhai Jadeja as an Additional Director (Non-Executive and Independent) effective 13 Jul'26. The appointment is for a five-year term, subject to shareholder approval within three months. Mr. Jadeja brings over a decade of financial management and accounting experience, previously serving as Head of Accountant at Hindustan Project for nearly 13 years. He currently holds directorships at Golden Sparrow Consultancy and Sunrise Middle East Turn Tech Limited. He is not related to any existing directors.
The Exchange had sought clarification from Curis Lifesciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Financial Result · 09 Jul 2026, 5:21 pm
Curis Lifesciences Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 3,272 (-4.8% YoY | +17.2% QoQ) ■ EBITDA: 514 (-25.8% YoY | -14.1% QoQ) ■ EBITDA Margin (%): 15.7 (-446 bps YoY | -574 bps QoQ) ■ PBT: 436 (-27.3% YoY | -16.5% QoQ) ■ PAT: 271 (-32.4% YoY | -35.8% QoQ) ■ EPS (INR): 4.01 (-42.8% YoY | -43.5% QoQ)
Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 04 Jul 2026, 1:27 am
Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 04 Jul 2026, 1:18 am
Curis Lifesciences Limited has informed the Exchange regarding Cessation of Mr. Chand Rameshbhai Kanabar as Non- Executive Independent Director of the company w.e.f. July 03, 2026.
Change in Management · 04 Jul 2026, 12:01 am
Curis Lifesciences: Independent Director Chand Kanabar Resigns Mr. Chand Rameshbhai Kanabar has resigned as Independent Director of Curis Lifesciences, effective 03 Jul'26. The resignation is attributed to pre-occupancy and increased professional commitments. Mr. Kanabar confirmed there are no other material reasons for his departure. He continues to hold directorships at Accretion Pharmaceuticals and Kian-M Export, serving on multiple board committees for both entities, including the Audit and Nomination and Remuneration Committees. The company is now tasked with finding a replacement to maintain board compliance.
Curis Lifesciences Limited has informed the Exchange about General Updates
Others (Uncategorized) · 01 Jul 2026, 9:49 pm
Curis Lifesciences Fined by NSE for Compliance Delay Curis Lifesciences has been fined Rs. 5,900 by the National Stock Exchange (NSE) for delayed compliance with Regulation 23(9) of SEBI Listing Regulations for the year ended March 2026. The company received the notification via email on 30th Jun'26 and must pay the fine within 15 days of the notice. The financial impact is limited to the penalty amount. This regulatory action pertains to disclosure of related party transactions.
The Exchange has sought clarification from Curis Lifesciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Others (Uncategorized) · 29 Jun 2026, 3:09 pm